Rossi Luigia, Serafini Sonja, Antonelli Antonella, Pierigé Francesca, Carnevali Andrea, Battistelli Valeria, Malatesta Manuela, Balestra Emanuela, Caliò Raffaele, Perno Carlo-Federico, Magnani Mauro
Institute of Biochemistry G. Fornaini, University of Urbino, 61029 Urbino (PU), Italy.
J Drug Target. 2005 Feb;13(2):99-111. doi: 10.1080/10611860500064123.
Given the important role of macrophages in various disorders, the transient and organ specific suppression of their functions may benefit some patients. Until now, liposome-encapsulated bisphosphonate clodronate has been extensively proposed to this end. In this paper, we demonstrate that erythrocytes loaded with clodronate can also be effective in macrophage depletion. Here, clodronate was encapsulated in erythrocytes through hypotonic dialysis, isotonic resealing and reannealing to final concentrations of 4.1 +/- 0.4 and 10.1 +/- 0.8 micromol/ml of human and murine erythrocytes, respectively. The ability of clodronate-loaded erythrocytes to deplete macrophages was evaluated both in vitro and in vivo. In vitro studies on human macrophages showed that a single administration of engineered erythrocytes was able to reduce cell adherence capacity in a time-dependent manner, reaching 50 +/- 4% reduction, 13 days post treatment. The administration of loaded erythrocytes to cultures of murine peritoneal macrophages was able to reduce macrophage adhesion 67 +/- 3%, 48 h post treatment. In vivo, the ability of clodronate-loaded erythrocytes to deplete macrophages was evaluated both in Swiss and C57BL/6 mice. Swiss mice received 125 microg of clodronate through erythrocytes and 6 days post treatment 69 +/- 7% reduction in the number of adherent peritoneal macrophages and 75 +/- 5% reduction in number of spleen macrophages were observed. C57BL/6 mice received 220 microg clodronate by RBC and 3 and 8 days post treatment 65 +/- 7% reduction in the number of spleen macrophages and the complete depletion of liver macrophages were obtained. In summary, our results indicate that clodronate selectively targeted to the phagocytic cells by a single administration of engineered erythrocytes is able to deplete macrophages, even if not completely. The transient suppression of macrophage functions through clodronate-loaded erythrocytes can be used in many biomedical phenomena and research applications.
鉴于巨噬细胞在各种疾病中发挥的重要作用,对其功能进行短暂且器官特异性的抑制可能会使部分患者受益。到目前为止,脂质体包裹的双膦酸盐氯膦酸盐已被广泛用于此目的。在本文中,我们证明负载氯膦酸盐的红细胞在巨噬细胞清除方面同样有效。在此,通过低渗透析、等渗重封和再退火将氯膦酸盐包裹在红细胞中,人红细胞和鼠红细胞的最终浓度分别为4.1±0.4和10.1±0.8微摩尔/毫升。对负载氯膦酸盐的红细胞清除巨噬细胞的能力进行了体外和体内评估。对人巨噬细胞的体外研究表明,单次给予工程化红细胞能够以时间依赖性方式降低细胞黏附能力,治疗后13天降低幅度达到50±4%。将负载红细胞给予鼠腹膜巨噬细胞培养物后,治疗后48小时巨噬细胞黏附减少67±3%。在体内,在瑞士小鼠和C57BL/6小鼠中评估了负载氯膦酸盐红细胞清除巨噬细胞的能力。瑞士小鼠通过红细胞接受125微克氯膦酸盐,治疗后6天观察到腹膜黏附巨噬细胞数量减少69±7%,脾脏巨噬细胞数量减少75±5%。C57BL/6小鼠通过红细胞接受220微克氯膦酸盐,治疗后3天和8天脾脏巨噬细胞数量减少65±7%,并且肝脏巨噬细胞完全清除。总之,我们的结果表明,通过单次给予工程化红细胞将氯膦酸盐选择性靶向吞噬细胞能够清除巨噬细胞,即使不能完全清除。通过负载氯膦酸盐的红细胞对巨噬细胞功能进行短暂抑制可用于许多生物医学现象和研究应用。